Group 1 - On October 14, 15 companies announced 15 stock repurchase updates, with 6 companies disclosing repurchase plans for the first time, 3 plans approved by shareholders, 4 companies reporting implementation progress, and 2 completing their repurchase plans [1] - The highest proposed repurchase amounts from newly disclosed plans are from COSCO Shipping Holdings at 1.498 billion, Jiuan Medical at 600 million, and China National Chemical Engineering at 100 million [1] - Companies that received shareholder approval for their repurchase plans include Nearshore Protein with a proposed repurchase of up to 20 million, Haoshanghao at 266,400, and Runbei Aerospace Technology at 227,100 [1] Group 2 - The highest amounts repurchased from companies reporting implementation progress are from Ruikang Pharmaceutical at 69.3892 million, Qianwei Central Kitchen at 49.9827 million, and Baiwei Storage at 39.9905 million [1] - Completed repurchases include China Merchants Port at 389 million and Rongxin Culture at 21.999 million [2] - As of October 14, a total of 1,614 repurchase plans have been completed this year, involving 1,226 companies, with 312 companies having completed repurchases exceeding 100 million [2]

Core Viewpoint - Ruikang Pharmaceutical announced a share buyback plan, intending to repurchase 23.613117 million shares, which represents 1.57% of the company's total share capital as of September 30, 2025 [2] Group 1 - The company will conduct the share buyback through a dedicated securities account via centralized bidding [2] - The buyback is part of the company's strategy to enhance shareholder value [2]

Core Viewpoint - Ruikang Pharmaceutical (002589.SZ) announced a share buyback plan, repurchasing 23.613117 million shares, which represents 1.57% of the company's total share capital, with a total transaction amount of 69.3892 million yuan [1] Summary by Categories Share Buyback Details - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest transaction price was 3.08 yuan per share, while the lowest was 2.75 yuan per share [1] - The total amount spent on the buyback was 69.3892 million yuan, excluding transaction fees [1] Compliance and Regulations - The share buyback is in accordance with the company's established buyback plan and relevant laws and regulations [1]

每经头条（nbdtoutiao）——AI技术滥用调查：明星可被"一键换装"，"擦边"内容成流量密码，技术防 线为何形同虚设？ 2025年1至6月份，瑞康医药的营业收入构成为：药品及器械销售占比98.42%，移动医疗占比0.67%，其 他占比0.6%，租赁占比0.31%。 （记者 曾健辉） 每经AI快讯，瑞康医药（SZ 002589，收盘价：2.86元）10月13日晚间发布公告称，截至2025年9月30 日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份约2361.31万股，占公司目前总股本 的1.57%，最高成交价3.08元/股，最低成交价2.75元/股，成交总金额6938.92万元。 截至发稿，瑞康医药市值为43亿元。 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-049 瑞康医药集团股份有限公司 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编 号：2024-037）、2024 年 12 月 12 日在巨潮资讯网披露《回购报告书》（公告编 号：2024-048）。 根据《上市公司股 ...

Core Insights - Ruikang Pharmaceutical (002589) reported that as of September 19, 2025, the number of shareholders reached 73,032 [1] Company Summary - Ruikang Pharmaceutical's shareholder count indicates a growing interest and potential investor confidence in the company [1]

山东乾元律师事务所·法律意见书 关于瑞康医药集团股份有限公司 2025 年第一次临时股东会的律师见证法律意见书 致：瑞康医药集团股份有限公司 山东乾元律师事务所（以下简称"本所"）接受贵公司的委托，指派 时晓旸、衣超律师（以下简称"本所律师"）出席贵公司于 2025 年 9 月 22 日下午 15 点在位于山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室举行 的 2025 年第一次临时股东会（以下简称"本次股东会"），并根据《中华 人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》 及《上市公司股东会规则》等法律法规及规范性文件和《瑞康医药集团股 份有限公司章程》（以下简称"《公司章程》"）的规定，就本次股东会 的召集与召开程序、出席会议人员的资格和召集人的资格、审议事项以及 表决方式、表决程序、表决结果依法进行见证，并出具法律意见。 为出具本法律意见书，本所律师审查了贵公司提供的以下文件，包括: 1、贵公司的《公司章程》； 2、贵公司于 2025 年 9 月 5 日召开的第五届董事会第十八次会议决议； 3、贵公司于 2025 年 9 月 6 日在《证券时报》、《中国证券报》、《证 券日 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-048 瑞康医药集团股份有限公司 2025 年第一次临时股东会决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述和重大遗漏。 一、 重要提示 1、本次股东会未涉及变更以往股东会已通过的决议。 2、本次股东会召开期间没有增加、否决或变更议案的情况发生。 二、 会议通知情况 《瑞康医药集团股份有限公司关于召开 2025 年第一次临时股东会的通知》 于 2025 年 9 月 6 日在《证券时报》、《中国证券报》、《证券日报》、《上海 证券报》和巨潮资讯网上已经披露。 三、 会议召开基本情况 1、会议召集人：公司董事会 2、会议时间：2025 年 9 月 22 日（星期一）下午 15:00 3、会议召开地点：山东省烟台市芝罘区凤鸣路 103 号 13 号楼会议室 4、会议主持人：董事长、总裁韩旭先生 5、会议召开方式：现场会议结合网络投票方式 6、本次会议的召集、召开符合《公司法》、《上市公司股东会规则》、《深 圳证券交易所股票上市规则》及《公司章程》等有关法律、法规及规范性文件的 规定。 四、 会议出席情况 ...

Market Overview - The pharmaceutical commercial sector increased by 0.19% on September 16, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Top Gainers - Saily Medical (603716) closed at 31.80, up 5.75% with a trading volume of 461,500 shares and a transaction value of 1.457 billion [1] - First Pharmaceutical (600833) closed at 14.33, up 3.47% with a trading volume of 159,400 shares and a transaction value of 229 million [1] - Ruikang Pharmaceutical (002589) closed at 3.05, up 2.35% with a trading volume of 564,800 shares and a transaction value of 170 million [1] Other Notable Stocks - Haiwang Biological (000078) closed at 2.72, up 1.87% with a trading volume of 472,600 shares and a transaction value of 128 million [1] - Yiyigou (300937) closed at 28.06, up 1.41% with a trading volume of 13,100 shares and a transaction value of 36.54 million [1] Market Capital Flow - The pharmaceutical commercial sector saw a net inflow of 1.0663 million from institutional investors, while retail investors had a net inflow of 3.2772 million [2] - However, speculative funds experienced a net outflow of 33.8383 million [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 99.8444 million from institutional investors, while it faced a net outflow of 39.1679 million from speculative funds [3] - First Pharmaceutical saw a net inflow of 21.4721 million from institutional investors, but a net outflow of 2.02355 million from retail investors [3] - Ruikang Pharmaceutical had a net inflow of 8.2730 million from institutional investors, with a slight net outflow from speculative funds [3]

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]